<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02230189</url>
  </required_header>
  <id_info>
    <org_study_id>14-14224</org_study_id>
    <secondary_id>5U19AI077439</secondary_id>
    <nct_id>NCT02230189</nct_id>
  </id_info>
  <brief_title>Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics</brief_title>
  <acronym>ACE</acronym>
  <official_title>Mechanistic Study of Epithelial miRNAs and T-cell Recruitment Dynamics That Occur After Allergen Challenge in Patients With Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prescott Woodruff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol describes a single site mechanistic study to investigate microRNAs (miRNAs)&#xD;
      that are differentially expressed in the airway epithelium of patients with asthma at&#xD;
      baseline and in response to allergen challenge. We hypothesize that allergen exposure&#xD;
      enhances airway smooth muscle contractility and epithelial cell mRNA/miRNA production as a&#xD;
      consequence of locally increased T-cell derived cytokine production. The study will involve&#xD;
      three visits over the course of approximately 14 days. At Visit 1, participants will be&#xD;
      characterized in detail with lung function testing, methacholine challenge testing, and&#xD;
      allergen skin prick testing. At Visit 2, participants will undergo bronchoscopy with&#xD;
      segmental allergen administration of either cat or dust mite standardized allergen extract.&#xD;
      At Visit 3 (either 24 hours later or 7 days later), bronchoscopy will be performed to collect&#xD;
      airway samples including bronchoalveolar lavage (BAL), epithelial brushings and endobronchial&#xD;
      biopsies. Sample analysis will include measurement of miRNA and mRNA expression in epithelial&#xD;
      brushings (RNAseq and qPCR); analysis of cell surface markers on BAL cells and blood cells;&#xD;
      and collection of endobronchial biopsies for immunostaining of immune cells localization,&#xD;
      immunoblotting of smooth cell protein phosphorylation, analysis of mucin content and smooth&#xD;
      muscle cell subculture. A total of 38 subjects (26 asthmatics with stable or well-controlled&#xD;
      asthma, 6 allergic non-asthmatics and 6 non-allergic non-asthmatics) will complete the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in expression of epithelial miRNAs (in read counts) after allergen-challenge as compared to after diluent challenge</measure>
    <time_frame>24 hours or 7 days</time_frame>
    <description>After processing of the sequencing data to read counts, the difference in read count in the allergen challenged as compared to the diluent challenged segment at the given follow-up time point will be calculated for each subject. The change in read count for each miRNA in the allergen samples will be compared to the change in read count in the diluent samples and statistical significance will be assessed using the Benjamini Hochberg false discovery rate method (FDR) to account for multiple comparisons.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Non-allergic/Non-asthmatic subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Segmental airway allergen challenge Group: Volunteers with neither asthma nor allergy (as established by skin prick testing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergic/Non-asthmatic subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Segmental airway allergen challenge Group: Volunteers with allergy (as established by skin prick testing) but without asthma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergic/Asthmatic subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Segmental airway allergen challenge Group: Volunteers with both asthma and allergy (as established by skin prick testing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Segmental airway allergen challenge</intervention_name>
    <arm_group_label>Allergic/Asthmatic subjects</arm_group_label>
    <arm_group_label>Allergic/Non-asthmatic subjects</arm_group_label>
    <arm_group_label>Non-allergic/Non-asthmatic subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Allergic/Non-Asthmatic subjects and Allergic/Asthmatic subjects&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive skin test to dust mite or cat allergen&#xD;
&#xD;
        Non-Allergic/Non-Asthmatic subjects&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Negative skin test to panel of 12 allergens, including dust mite and cat allergen&#xD;
&#xD;
        All groups&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of intubation for asthma exacerbation&#xD;
&#xD;
          -  Use of Xolair (omalizumab) within the last 6 months&#xD;
&#xD;
          -  Immunotherapy with cat or dust mite extract now or in the past 5 years&#xD;
&#xD;
          -  â‰¥ 10 pack-years smoking or any smoking in the past year&#xD;
&#xD;
          -  Other lung diseases, such as sarcoidosis, bronchiectasis or active lung infection&#xD;
&#xD;
          -  History of dermatographia&#xD;
&#xD;
          -  History of anaphylaxis to cat allergen&#xD;
&#xD;
          -  Participation in another research study involving a drug or biologic during the past&#xD;
             30 days&#xD;
&#xD;
          -  Presence of past or current medical problems/other factors that may pose additional&#xD;
             risks from participation or influence study results, as determined per study&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prescott G Woodruff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://acrc.ucsf.edu/</url>
    <description>UCSF Airway Clinical Research Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 28, 2014</study_first_submitted>
  <study_first_submitted_qc>August 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2014</study_first_posted>
  <disposition_first_submitted>January 29, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>January 29, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 2, 2021</disposition_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Prescott Woodruff</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Allergen challenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

